Q4 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks
Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics earnings season.
News
Spotting Winners: TreeHouse Foods (NYSE:THS) And Shelf-Stable Food Stocks In Q4
Let’s dig into the relative performance of TreeHouse Foods (NYSE:THS) and its peers as we unravel the now-completed Q4 shelf-stable food earnings season.
3 Reasons to Avoid ADT and 1 Stock to Buy Instead
ADT has had an impressive run over the past six months. While the S&P 500 has been flat, the stock has returned 9.2% and now trades at $7.92. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
3 Reasons to Sell STE and 1 Stock to Buy Instead
STERIS currently trades at $226.40 per share and has shown little upside over the past six months, posting a small loss of 4.5%.
3 Reasons QTWO is Risky and 1 Stock to Buy Instead
Q2 Holdings has been treading water for the past six months, recording a small loss of 4.1% while holding steady at $78.18.
Q4 Earnings Highs And Lows: First Solar (NASDAQ:FSLR) Vs The Rest Of The Renewable Energy Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at First Solar (NASDAQ:FSLR) and its peers.
3 Reasons to Avoid HNST and 1 Stock to Buy Instead
The past six months have been a windfall for The Honest Company’s shareholders. The company’s stock price has jumped 44.3%, hitting $5.34 per share. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.